Mapi Pharma is a clinical-stage pharmaceutical company developing proprietary pharmaceuticals, including lifecycle management products such as Depot long-acting injections, complex active pharmaceutical ingredients, and formulations. The company’s lead product is Glatiramer Acetate Depot, a once-monthly injection for the treatment of patients with multiple sclerosis. Mapi is also engaged in the development of Pregabalin ER for the treatment of neuropathic pain and epilepsy, Paliperidone Palmitate and Buspirone ER for the treatment of schizophrenia, and other long-acting Depot injectable treatments.